Neurocrine Biosciences (NBIX) Cash & Equivalents Growth (3y) (2013 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Cash & Equivalents Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.48 Bn | 625.73 Bn | 17.26 Bn | -1.21% |
| 2 | AbbVie | 442.74 Bn | 436.17 Bn | 12.70 Bn | -9.15% |
| 3 | Merck | 366.39 Bn | 359.25 Bn | 12.21 Bn | 6.56% |
| 4 | Novartis Ag | 266.55 Bn | 258.86 Bn | 11.24 Bn | -11.22% |
| 5 | Pfizer | 158.80 Bn | 147.10 Bn | 10.94 Bn | -28.16% |
| 6 | Sanofi | 52.34 Bn | 44.96 Bn | 10.79 Bn | -5.35% |
| 7 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 8 | Incyte | 25.42 Bn | 20.88 Bn | 1.57 Bn | 8.35% |
| 9 | United Therapeutics | 21.53 Bn | 18.87 Bn | 683.80 Mn | 19.10% |
| 10 | Neurocrine Biosciences | 15.60 Bn | 15.21 Bn | 935.80 Mn | 27.55% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 27.55% |
| Mar 31, 2026 | 36.93% |
| Dec 31, 2025 | 38.10% |
| Sep 30, 2025 | 17.04% |
| Jun 30, 2025 | 17.37% |
| Mar 31, 2025 | -10.44% |
| Dec 31, 2024 | -12.18% |
| Sep 30, 2024 | 3.92% |
| Jun 30, 2024 | -27.59% |
| Mar 31, 2024 | 3.97% |
| Dec 31, 2023 | 10.83% |
| Sep 30, 2023 | -11.61% |
| Jun 30, 2023 | -27.19% |
| Mar 31, 2023 | -18.28% |
| Dec 31, 2022 | 32.83% |
| Sep 30, 2022 | 8.39% |
| Jun 30, 2022 | 5.02% |
| Mar 31, 2022 | 54.84% |
| Dec 31, 2021 | 34.39% |
| Sep 30, 2021 | 16.70% |